ARHGEF26-AS1

Across TCGA pan-cancer cohorts, ARHGEF26-AS1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ARHGEF26-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARHGEF26-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types ARHGEF26-AS1 is over-expressed in tumor, although a few such as KIRC and LUSC show the opposite, repressed pattern.

KIRC, LUSC, and LUAD are the cancer types where ARHGEF26-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF26-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−0.358	<.001	12	view →
LUSC	Female	II,III,IV	−1.627	<.001	9	view →
LUAD	Male	II,III,IV	−0.943	<.001	8	view →
STAD	All	All	−0.494	.001	5	view →
KICH	All	All	−0.216	<.001	5	view →
UCEC	All	All	−0.554	.008	4	view →
BRCA	All	II,III,IV	+0.375	<.001	4	view →
COAD	Male	II,III,IV	−0.356	.002	4	view →
LIHC	Female	All	−0.158	<.001	4	view →
PRAD	All	All	+0.530	<.001	2	view →
THCA	All	All	+0.300	.005	2	view →
ESCA	Female	All	−0.229	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ARHGEF26-AS1–KIRC

Open the KIRC breakdown →